Stock BIOM3 BIOMM S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Market Closed - Sao Paulo
Other stock markets
 01:43:43 29/06/2024 am IST 		5-day change 1st Jan Change
14.87 BRL -9.11% Intraday chart for Biomm S.A. +6.98% +157.27%
16/05 Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
18/04 Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil
MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biomm S A : Webcast Presentation 3Q23
PU
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Biomm S A : Apresentação de resultados 2T23
PU
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar
CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Biomm S A : Presentation of 1Q22 Results
PU
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Biomm S A : Comunicado ao Mercado
PU
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil
MT
CytoDyn : Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOM3 Stock
  4. News Biomm S.A.